Efficacy of Intensity-Modulated Radiotherapy with concurrent carboplatin in nasopharyngeal carcinoma

  • Anussara Prayongrat Songthong Division of Radiation Oncology, Department of Radiology, Chulalongkorn University, Chulalongkorn Hospital
  • Chakkapong Chakkabat Division of Radiation Oncology, Department of Radiology, Chulalongkorn University, Chulalongkorn Hospital
  • Danita Kannarunimit Division of Radiation Oncology, Department of Radiology, Chulalongkorn University, Chulalongkorn Hospital
  • Chawalit Lertbutsayanukul Division of Radiation Oncology, Department of Radiology, Chulalongkorn University, Chulalongkorn Hospital

Abstract

Purpose: To evaluate the efficacy and toxicities of concurrent carboplatin with Intensity-Modulated Radiotherapy (IMRT) in the treatment of NPC.

Materials and Methods: Between October 2005 and November 2011, 73 stage II-IVB NPC patients received IMRT 70 Gy concurrently with three cycles of carboplatin (AUC5) every three weeks, followed by three cycles of adjuvant carboplatin (AUC5) and 5-FU (1,000 mg/m2/day for four days) every four weeks. All patients were evaluated for tumor response using RECIST criteria, survival analysis using Kaplan-Meier methods, and toxicities according to CTCAE version 4.0.

Results: At three months after chemoradiation, 82.2% and 17.8% achieved complete and partial response, respectively. With a median follow-up of 48.1 months (1.3-97.8 months), 8.2% and 17.8% had local recurrence and distant metastasis. Median survival was not reached. Three-year overall survival and progression-free survival were 83.6% and 65.3%. Regarding treatment compliance, 97.2%, 69.9% and 68.5% completed radiation treatment, concurrent carboplatin and adjuvant chemotherapy, respectively. Grade 3-4 acute toxicities were oral mucositis (16.4%), dysphagia (16.4%), xerostomia (15.1%) and hematotoxicity (6.8%).

Conclusion: Giving carboplatin concurrently with IMRT provided excellent tumor response, manageable toxicities and good compliance. This should be considered as an alternative treatment for NPC patients.

Author Biographies

Anussara Prayongrat Songthong, Division of Radiation Oncology, Department of Radiology, Chulalongkorn University, Chulalongkorn Hospital

M.D.

Division of Radiation Oncology, Department of Radiology, Chulalongkorn Hospital, Pathumwan, Bangkok, Thailand.

Chakkapong Chakkabat, Division of Radiation Oncology, Department of Radiology, Chulalongkorn University, Chulalongkorn Hospital

M.D.

Division of Radiation Oncology, Department of Radiology, Chulalongkorn University, Chulalongkorn Hospital, Pathumwan, Bangkok, Thailand.

Danita Kannarunimit, Division of Radiation Oncology, Department of Radiology, Chulalongkorn University, Chulalongkorn Hospital

M.D.

Division of Radiation Oncology, Department of Radiology, Chulalongkorn University, Chulalongkorn Hospital, Pathumwan, Bangkok, Thailand.

Chawalit Lertbutsayanukul, Division of Radiation Oncology, Department of Radiology, Chulalongkorn University, Chulalongkorn Hospital

Assoc. Prof., M.D.

Division of Radiation Oncology, Department of Radiology, Chulalongkorn University, Chulalongkorn Hospital, Pathumwan, Bangkok, Thailand.

Published
2015-04-24
How to Cite
Songthong, A. P., Chakkabat, C., Kannarunimit, D., & Lertbutsayanukul, C. (2015). Efficacy of Intensity-Modulated Radiotherapy with concurrent carboplatin in nasopharyngeal carcinoma. Radiology and Oncology, 49(2). Retrieved from https://www.radioloncol.com/index.php/ro/article/view/2194
Section
Clinical oncology